INDIANAPOLIS (dpa-AFX) - Amylin Pharmaceuticals Inc. (AMLN), Eli Lilly and Co. (LLY) and Alkermes Inc. (ALKS) Friday announced additional results from a phase 2 study of an investigational, once-monthly injectable suspension formulation of exenatide.
Exenatide once monthly is an investigational, extended-release formulation of exenatide, the active ingredient in Byetta (exenatide) injection, which is given twice daily.
The study showed substantial improvements in glycemic control, including reductions in A1C and fasting plasma glucose, with modest weight loss.
The 121-patient study assessed the efficacy, safety and tolerability of three different doses, i.e. 5 mg, 8 mg and 11 mg, of exenatide once monthly, a long-acting glucagon-like peptide-1 receptor agonist.
After 20 weeks of treatment, patients receiving exenatide once monthly experienced average improvements in A1C, a measure of average blood sugar over three months.
Patients also lost a modest amount of weight although exenatide once monthly is not being studied as a weight-loss product.
Copyright RTT News/dpa-AFX